Prevalence of Vigabatrin-Induced Visual Field Loss

Coleman of vigabatrin induced visual field defects

http://bjo.bmj.com/content/86/8/931.full.html Updated information and services can be found at: These include: References http://bjo.bmj.com/content/86/8/931.full.html#ref-list-1 This article cites 3 articles, 2 of which can be accessed free at: service Email alerting the top right corner of the online article. Receive free email alerts when new articles cite this article. Sign up in the box at...

Visual field loss associated with vigabatrin: pathological correlations.

Pathological changes are reported in the anterior visual pathways of a 41 year old man with complex partial seizures treated with vigabatrin who developed bilateral visual field constriction. There was peripheral retinal atrophy with loss of ganglion cells and loss of nerve fibres in the optic nerves, chiasm, and tracts. No evidence of intramyelinic oedema was seen. These findings suggest that ...

Visual field defects associated with vigabatrin therapy.

OBJECTIVE To estimate the prevalence of visual field defects in patients taking the anticonvulsant drug vigabatrin and to characterise the features of visual dysfunction found. METHODS Thirty three unselected patients attending neurology and epilepsy clinics were identified as taking vigabatrin and asked to attend for neuro-ophthalmic evaluation. A control group of 16 patients with epilepsy u...

Evolution of visual field loss over ten years in individuals taking vigabatrin

PURPOSE Vigabatrin-associated visual field loss (VAVFL) occurs in around 45% of exposed people. It is generally accepted that, once established, VAVFL is stable and does not progress with continued VGB use. Most studies have, however, only followed people for short periods. We assessed the evolution of VAVFL over a ten-year period of continued VGB use. METHODS From a group of 201 vigabatrin-e...

Vigabatrin-associated Visual Field Loss (vavfl): What You Need to Know